Pasithea Therapeutics Corp.
KTTANasdaq
$0.45
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↓ -35.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.0M
Enterprise Value
-$39.4M
P/E
—
P/S
—
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-36.0%
ROIC
-394.9%
Debt / Equity
—
Net Cash
$50.4M
Return 1Y
-34.9%
Company profile
Pasithea Therapeutics Corp. engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.
- CEO
- Tiago R. Marques
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- California
- Website
- pasithea.com
Management & directors
- Marques TiagoChief Executive Officer
- Schneiderman Daniel HChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
KTTA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.12↓ -92.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $15,062.00 | $486,559.00 | — | — | — |
| Gross profit | -$2,213.00 | — | — | — | — |
| Operating income | -$4.5M | -$12.6M | -$16.0M | -$14.2M | -$20.9M |
| Net income | -$2.2M | -$13.9M | -$16.0M | -$13.9M | -$20.4M |
| Diluted EPS | -$0.21 | -$1.76 | -$0.42 | -$12.69 | -$2.91 |
| Operating cash flow | -$3.2M | -$14.6M | — | -$13.9M | -$15.2M |
| Free cash flow | -$3.2M | -$14.7M | — | — | — |
| Gross margin | -14.7% | — | — | — | — |
| Operating margin | -29925.7% | -2587.3% | — | — | — |
| Net margin | -14430.5% | -2864.3% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.9M | -$3.0M | -$3.3M | -$3.7M | -$3.8M | -$3.1M | -$10.3M | -$4.9M |
| Net income | -$3.9M | -$3.0M | -$3.2M | -$3.6M | -$3.7M | -$3.0M | -$10.1M | -$2.9M |
| Diluted EPS | -$3.71 | -$2.87 | -$2.41 | -$1.61 | -$0.66 | -$0.41 | -$0.23 | -$0.12 |
| Operating cash flow | -$4.0M | -$3.1M | -$2.4M | -$3.1M | -$3.9M | -$2.9M | -$5.4M | -$4.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Coastlands Capital LP | Buy | 100,000 | $0.53 | $53,000.00 | filing |
| 2025-11-28 | STEINMAN LAWRENCE | Buy | 133,333 | $0.75 | $99,999.75 | filing |
| 2025-11-28 | Marques Tiago· Chief Executive Officer | Buy | 33,333 | $0.75 | $24,999.75 | filing |
| 2025-11-28 | Dumesnil Simon | Buy | 33,333 | $0.75 | $24,999.75 | filing |
| 2025-11-28 | Leahy Emer | Award | 33,333 | $0.75 | $24,999.75 | filing |
| 2025-11-28 | Schneiderman Daniel H· Chief Financial Officer | Award | 26,667 | $0.75 | $20,000.25 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.